drugset / Trial / NCT00040274

A Study of DPC 817 in HIV-Infected Males

NCT00040274 ↗

Phase 1 Completed 30 enrolled Pharmasset
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate DPC 817. The safety, dosages, and how the body responds to the drug will be studied.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexelvucitabine Small molecule — Oral